Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Next Previous
Trial Profile

A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EZM-0414 (Primary)
  • Indications Diffuse large B cell lymphoma; Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Epizyme

Most Recent Events

  • 30 Oct 2024 Status changed from active, no longer recruiting to discontinued as per business decision.
  • 01 Oct 2024 Status changed from recruiting to active, no longer recruiting.
  • 09 Aug 2022 According to an Epizyme media release, company anticipates providing longer term follow-up data from the Phase 1b portion of the study at a medical conference later this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top